Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: PrEP Considerations in Cisgender Men and Transgender Women

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of PrEP in cisgender men and transgender women. Topics include current data and recommendations for the use of oral and long-acting injectable PrEP options.
Latesha Elopre, MD, MSPH
Karine Lacombe, MD, PhD
Released: March 25, 2022

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:

  • Discussion of the PrEP gap and racial and gender disparities in PrEP access
  • CDC, EACS, and WHO guidance on PrEP eligibility
  • PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
  • Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD
  • Data from the ANRS IPERGAY study on the use of FTC/TDF on demand
  • Data from the DISCOVER trial on the use of FTC/TAF for PrEP
  • Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men
  • Clinical monitoring and considerations during PrEP use

Information on this Educational Activity

Faculty

Latesha Elopre, MD, MSPH

Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama

Latesha Elopre, MD, MSPH, has disclosed that she has received funds for research support from Merck.
Karine Lacombe, MD, PhD

Professor
UMR-S1136
Sorbonne University
Professor
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from Gilead Sciences, GlaxoSmithKline, Janssen, and MSD.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Clinical Care Options (CCO) downloadable slides from Dr Darrell Tan, providing an overview of available long-acting ART for HIV treatment and prevention

Babafemi Taiwo, MBBS
Program Director Darrell H. S. Tan, MD, FRCPC, PhD Released: June 14, 2022

Clinical Care Options (CCO) downloadable slides from Cristina Mussini, MD, providing practical insights into implementing long-acting ART into HIV care

Babafemi Taiwo, MBBS
Program Director Cristina Mussini, MD Released: June 14, 2022

Clinical Care Options (CCO) downloadable slides from Yvonne Gilleece providing an overview of investigational long-acting HIV care and prevention approaches

Babafemi Taiwo, MBBS
Program Director person default Yvonne Gilleece, MB BCh, BAO Released: June 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings